While discussing Amarin, will the company find a partner to help launch Vascepa, or perhaps a buyer? New drug launches to watch in the last four months of 2012: Medivation's Xtandi, Ironwood Pharmaceuticals' ( IRWD) Linzess, Onyx Pharma's ( ONXX) Kyprolis and Vivus' ( VVUS) Qsymia. I can't mention Vivus and ignore Arena Pharmaceuticals ( ARNA), which is expected to receive DEA scheduling for Belviq before the end of the year so that the obesity drug can be launched early in 2013. Will Peregrine Pharmaceuticals ( PPHM) sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised? Same goes for YM BioSciences ( YMI): Where is the promised partner to co-develop the myelobfibrosis drug CYT387? Can Idenix Pharmaceuticals ( IDIX) gather enough safety data to convince FDA to lift the clinical hold on its hepatitis C drugs? Will Achillion Pharmaceuticals ( ACHN), which like Idenix is seeking partners or buyers for its hepatitis C drugs, finally change its Facebook status to "In a Relationship?" --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.